rs150672767
Variant summary
Our verdict is Benign. Variant got -13 ACMG points: 0P and 13B. BP4_StrongBP6BS1BS2
The NM_002838.5(PTPRC):c.3670G>A(p.Val1224Ile) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00149 in 1,611,676 control chromosomes in the GnomAD database, including 9 homozygotes. In-silico tool predicts a benign outcome for this variant. 12/19 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. V1224V) has been classified as Likely benign.
Frequency
Consequence
NM_002838.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -13 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PTPRC | NM_002838.5 | c.3670G>A | p.Val1224Ile | missense_variant | 33/33 | ENST00000442510.8 | NP_002829.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PTPRC | ENST00000442510.8 | c.3670G>A | p.Val1224Ile | missense_variant | 33/33 | 1 | NM_002838.5 | ENSP00000411355.3 |
Frequencies
GnomAD3 genomes AF: 0.00150 AC: 228AN: 151842Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00194 AC: 485AN: 250252Hom.: 1 AF XY: 0.00208 AC XY: 282AN XY: 135264
GnomAD4 exome AF: 0.00149 AC: 2176AN: 1459716Hom.: 9 Cov.: 31 AF XY: 0.00152 AC XY: 1106AN XY: 726312
GnomAD4 genome AF: 0.00150 AC: 228AN: 151960Hom.: 0 Cov.: 32 AF XY: 0.00136 AC XY: 101AN XY: 74256
ClinVar
Submissions by phenotype
not provided Uncertain:2Benign:3
Likely benign, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, University Medical Center Utrecht | - | - - |
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jan 01, 2019 | - - |
Likely benign, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Aug 24, 2017 | The V1222I variant in the PTPRC gene has not been reported previously as a pathogenic variant, nor as a benign variant, to our knowledge. The V1222I variant is observed in 164/66528 (0.247%) alleles from individuals of non-Finnish European background in the ExAC dataset, and no individuals are reported to be homozygous (Lek et al., 2016). The V1222I variant is a conservative amino acid substitution, which is not likely to impact secondary protein structure as these residues share similar properties. This substitution occurs at a position where amino acids with similar properties to Valine are tolerated across species. In silico analysis predicts this variant likely does not alter the protein structure/function. We interpret V1222I as a variant of uncertain significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Jun 23, 2017 | The p.Val1224Ile variant has not been reported in the scientific medical literature or gene specific variant databases. This variant (rs150672767) is listed in the Exome Aggregation Consortium with an overall allele frequency of 0.16 percent. Valine at codon 1224 is weakly conserved considering 10 species (Alamut software v2.7.1), and Orangutan, Rhesus, Baboon, Mouse and Xenopus tropicalis all have isoleucine, suggesting that this amino acid change may be evolutionary tolerated. Additionally, computational analyses do not agree in their assessment of the impact on the protein (PolyPhen2: benign, SIFT: tolerated, and Mutation Taster: disease causing). Thus, even though the conservation and computational data suggest that this variant may represent a benign polymorphism, the clinical significance of p.Val1224Ile variant cannot be determined with certainty. Pathogenic variants in PTPRC are causative for severe combined immunodeficiency (MIM: 608971), and are inherited in autosomal recessive manner. Thus, even if p.Val1224Ile was subsequently determined to be pathogenic, based on the available information, this patient would be a carrier, and may be affected if a second pathogenic PTPRC variant is present on the opposite chromosome but could not be detected by this assay (eg, deep intronic variants, or regulatory region variants). - |
not specified Benign:1
Benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jul 12, 2022 | - - |
PTPRC-related disorder Benign:1
Benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Sep 26, 2019 | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Immunodeficiency 104 Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at